Literature DB >> 34602949

Double Heterozygous Mutations in the BRCA2 and ATM Genes: A Case Report and Review of the Literature.

Neslihan Duzkale Teker1, Nilnur Eyerci2.   

Abstract

INTRODUCTION: Germline mutations of the BRCA1 and BRCA2 genes are responsible for about a quarter of hereditary breast cancers (BCs). In this study, we aimed to determine the importance of rare double heterozygous (DH) pathogenic variant carriership in BRCA2and ATM genes in a patient diagnosed with BC and pancreas cancer (PC). CASE REPORT: A 54-year-old female patient was diagnosed with BC at the age of 34 years and with PC at the age of 48 years. The multigene panel and next-generation sequencing technique were used to evaluate the status of the patient's cancer susceptibility genes. Pathogenic variants c.537dup (p.Ile180Tyrfs*3) in the BRCA2 gene and c.5065C>T (p.Gln1689Ter) in the ATM gene were detected as DH in the patient. Co-segregation analysis was performed on the relatives of the patient using Sanger sequencing. DISCUSSION/
CONCLUSION: Multiple primary malignant neoplasms can be encountered more frequently in DH pathogenic variant carriers, and the diagnosis of malignancies can be made at an earlier age through surveillance guided by genetic testing. In this rare case, more patient studies are needed to determine the contribution of DH in BRCA2 and ATM genes to the phenotype.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  ATM; BRCA; Breast cancer; Multiple primary malignant neoplasia; Pancreas cancer

Year:  2020        PMID: 34602949      PMCID: PMC8436619          DOI: 10.1159/000511430

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.268


  32 in total

1.  Atm heterozygosity cooperates with loss of Brca1 to increase the severity of mammary gland cancer and reduce ductal branching.

Authors:  T J Bowen; Hiroyuki Yakushiji; Cristina Montagna; Sonia Jain; Thomas Ried; Anthony Wynshaw-Boris
Journal:  Cancer Res       Date:  2005-10-01       Impact factor: 12.701

2.  The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries.

Authors:  Yael Laitman; Tara M Friebel; Drakoulis Yannoukakos; Florentia Fostira; Irene Konstantopoulou; Gisella Figlioli; Bernardo Bonanni; Siranoush Manoukian; Monica Zuradelli; Carlo Tondini; Barbara Pasini; Paolo Peterlongo; Dijana Plaseska-Karanfilska; Milena Jakimovska; Keivan Majidzadeh; Shiva Zarinfam; Maria A Loizidou; Andreas Hadjisavvas; Kyriaki Michailidou; Kyriacos Kyriacou; Doron M Behar; Rinat Bernstein Molho; Patricia Ganz; Paul James; Michael T Parsons; Aminah Sallam; Olufunmilayo I Olopade; Arun Seth; Georgia Chenevix-Trench; Goska Leslie; Lesley McGuffog; Makia J Marafie; Andre Megarbane; Fahd Al-Mulla; Timothy R Rebbeck; Eitan Friedman
Journal:  Hum Mutat       Date:  2019-07-26       Impact factor: 4.878

3.  Rate of BRCA mutation in patients tested under NCCN genetic testing criteria.

Authors:  Anna C Beck; Haimiao Yuan; Junlin Liao; Pamela Imperiale; Krysten Shipley; Lillian M Erdahl; Sonia L Sugg; Ronald J Weigel; Ingrid M Lizarraga
Journal:  Am J Surg       Date:  2019-06-19       Impact factor: 2.565

4.  Hemizygosity for Atm and Brca1 influence the balance between cell transformation and apoptosis.

Authors:  Fengtao Su; Lubomir B Smilenov; Thomas Ludwig; Libin Zhou; Jiayun Zhu; Guangming Zhou; Eric J Hall
Journal:  Radiat Oncol       Date:  2010-02-22       Impact factor: 3.481

5.  Incidence of cancer in 161 families affected by ataxia-telangiectasia.

Authors:  M Swift; D Morrell; R B Massey; C L Chase
Journal:  N Engl J Med       Date:  1991-12-26       Impact factor: 91.245

6.  Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.

Authors:  Maryam Dosani; Kasmintan A Schrader; Alan Nichol; Sophie Sun; Tamara Shenkier; Zoe Lohn; Gudrun Aubertin; Scott Tyldesley
Journal:  Cureus       Date:  2017-07-11

7.  Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.

Authors:  Georgios N Tsaousis; Eirini Papadopoulou; Angela Apessos; Konstantinos Agiannitopoulos; Georgia Pepe; Stavroula Kampouri; Nikolaos Diamantopoulos; Theofanis Floros; Rodoniki Iosifidou; Ourania Katopodi; Anna Koumarianou; Christos Markopoulos; Konstantinos Papazisis; Vasileios Venizelos; Ioannis Xanthakis; Grigorios Xepapadakis; Eugeniu Banu; Dan Tudor Eniu; Serban Negru; Dana Lucia Stanculeanu; Andrei Ungureanu; Vahit Ozmen; Sualp Tansan; Mehmet Tekinel; Suayib Yalcin; George Nasioulas
Journal:  BMC Cancer       Date:  2019-06-03       Impact factor: 4.430

8.  Genetic and clinical characterization of BRCA-associated hereditary breast and ovarian cancer in Navarra (Spain).

Authors:  Ainara Ruiz de Sabando; Edurne Urrutia Lafuente; Fermín García-Amigot; Angel Alonso Sánchez; Lourdes Morales Garofalo; Sira Moreno; Eva Ardanaz; Maria A Ramos-Arroyo
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

9.  Evaluation of ATM heterozygous mutations underlying individual differences in radiosensitivity using genome editing in human cultured cells.

Authors:  Ekaterina Royba; Tatsuo Miyamoto; Silvia Natsuko Akutsu; Kosuke Hosoba; Hiroshi Tauchi; Yoshiki Kudo; Satoshi Tashiro; Takashi Yamamoto; Shinya Matsuura
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

10.  Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.

Authors:  Beth Crawford; Sophie B Adams; Taylor Sittler; Jeroen van den Akker; Salina Chan; Ofri Leitner; Lauren Ryan; Elad Gil; Laura van 't Veer
Journal:  Breast Cancer Res Treat       Date:  2017-03-09       Impact factor: 4.872

View more
  1 in total

1.  Double heterozygous pathogenic variants prevalence in a cohort of patients with hereditary breast cancer.

Authors:  Thais Baccili Cury Megid; Mateus C Barros-Filho; Janina Pontes Pisani; Maria Isabel Achatz
Journal:  Front Oncol       Date:  2022-08-08       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.